202 related articles for article (PubMed ID: 37082097)
1. Treatment outcomes of mucosal melanoma of head and neck: Efficacy of immune checkpoint inhibitors for advanced disease.
Ohshima S; Ueki Y; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Okabe R; Matsuyama H; Togashi T; Takatsuka S; Takenouchi T; Horii A
Front Surg; 2022; 9():1032626. PubMed ID: 37082097
[TBL] [Abstract][Full Text] [Related]
2. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification.
Shi C; Ju H; Zhou R; Xu S; Wu Y; Gu Z; Wang Y; Chen W; Huang X; Han Y; Sun S; Li C; Wang M; Zhou G; Zhang Z; Li J; Ren G
BMC Med; 2024 May; 22(1):215. PubMed ID: 38807144
[TBL] [Abstract][Full Text] [Related]
4. Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
Uematsu M; Nakajima H; Hosono A; Kiyohara H; Hirota A; Takahashi N; Fukuda M; Kusuhara S; Nakao T; Funasaka C; Kondoh C; Harano K; Matsubara N; Naito Y; Akimoto T; Mukohara T
Melanoma Res; 2023 Dec; 33(6):547-552. PubMed ID: 37696254
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
[TBL] [Abstract][Full Text] [Related]
6. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors.
Mesti T; Grašič Kuhar C; Ocvirk J
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979727
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody
Fujisaki T; Watanabe S; Ota T; Kushiro K; Sato Y; Takahashi M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Hokari S; Kondo R; Miyabayashi T; Abe T; Miura S; Tanaka H; Okajima M; Terada M; Matsumoto N; Ishida T; Iwashima A; Sato K; Yoshizawa H; Aoki N; Hayashi M; Ohshima Y; Koya T; Kikuchi T
Front Oncol; 2021; 11():704475. PubMed ID: 34631533
[TBL] [Abstract][Full Text] [Related]
9. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
10. The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.
Lev-Ari S; Serzan M; Wu T; Ip A; Pascual L; Sinclaire B; Adams S; Marafelias M; Ayyagari L; Gill SK; Ma B; Zaemes JP; Della Pia A; Alaoui A; Madhavan S; Belouali A; Pecora A; Ahn J; Atkins MB; Shah NJ
Cancer; 2023 Jun; 129(12):1885-1894. PubMed ID: 36951119
[TBL] [Abstract][Full Text] [Related]
11. Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition.
Kudura K; Basler L; Nussbaumer L; Foerster R
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291928
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study.
Haist M; Stege H; Pemler S; Heinz J; Fleischer MI; Graf C; Ruf W; Loquai C; Grabbe S
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680252
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
Foster CC; Couey MA; Kochanny SE; Khattri A; Acharya RK; Tan YC; Brisson RJ; Leidner RS; Seiwert TY
Cancer; 2021 Dec; 127(24):4565-4573. PubMed ID: 34547103
[TBL] [Abstract][Full Text] [Related]
15. New Zealand national retrospective cohort study of survival outcomes of patients with metastatic melanoma receiving immune-checkpoint inhibitors.
Ab Rahman AS; Strother RM; Paddison J
Asia Pac J Clin Oncol; 2023 Feb; 19(1):179-186. PubMed ID: 35686690
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
18. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
Kelly D; Rose AAN; Muniz TP; Hogg D; Butler MO; Saibil SD; King I; Kamil ZS; Ghazarian D; Ross K; Iafolla M; Araujo DV; Waldron J; Laperriere N; Krema H; Spreafico A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298857
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of immune checkpoint inhibitor treatment for head and neck mucosal melanoma recurrence in patients treated with carbon-ion radiotherapy.
Musha A; Kubo N; Kawamura H; Okano N; Sato H; Okada K; Tomizawa K; Ota N; Adachi A; Shino M; Nikkuni O; Ida S; Shirai K; Saitoh JI; Yokoo S; Chikamatsu K; Ohno T
Cancer Rep (Hoboken); 2023 Jul; 6(7):e1825. PubMed ID: 37115713
[TBL] [Abstract][Full Text] [Related]
20. Malignant Myoepithelioma of the Head and Neck: Demographics, Clinicopathological Characteristics, Treatment, and Prognosis.
Wang JQ; Deng RX; Liu H; Luo Y; Lu MM; Yang ZC
Front Oncol; 2022; 12():754967. PubMed ID: 35847870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
